Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study : vimarsana.com

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

RAS-mutated mCRC– In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulti...

Related Keywords

San Diego , California , United States , American , James Levine , Kiki Patel , Mark Erlander , Nasdaq , American Association For Cancer Research , Online Program , Gilmartin Group , Taft Communications , Cardiff Oncology Inc , American Association , Cancer Research , Chief Executive Officer , Bev Revealed , New Role , Hypoxia Pathway , Metastatic Colorectal , Open Label Study , Versus Soc Alone , First Line Treatment , Metastatic Colorectal Cancer Patient Derived , Small Cell Lung Cancer , Cardiff Oncology , Oncology Contact ,